Topic
Drug Discovery
19 published works
Joe Raczynski | Technologist
Beyond the Wet Lab Bottleneck: The Race to Build Biology’s Generative Engine
Cambridge, MA – MIT Media Lab – EmTech Future. Nature has spent roughly 3.8 billion years conducting the most sprawling, creative research and development campaign in history. Evolution engineered millions…
Healthcare Law Insights
Dealmaking in the Age of AI: IP, Licensing, and Spin-Out Strategies for AI-Enhanced Drug Discovery
This is the third in a series of blog posts focused on AI and clinical trials/research space, highlighting topics to be discussed at the upcoming BIO International convention on June…
Joe Raczynski | Technologist
AI at the Speed of Enterprise R&D: Isomorphic Labs and the Future of Drug Discovery
EmTechMIT, Cambridge, MA: In recent years, enterprise R&D in biotechnology has been fundamentally reshaped by the rise of artificial intelligence. At EmTechMIT, Chief Business & Legal Officer Sarah Korman of…
RF EMerge
Key IP Licensing Considerations for AI Drug Discovery Platforms
By Dan Shores, Michael Ellenberger
Background Artificial Intelligence (“AI”) has been utilized by innovative companies across the array of industry spaces, but its impact on biotech (and human health in general) could become the most…
Covington Digital Health
Quantum Computing and its Impact on the Life Science Industry
Quantum computing uses quantum mechanics principles to solve certain complex mathematical problems faster than classical computers. Whilst classical computers use binary “bits” to perform calculations, quantum computers use quantum bits…
Inside EU Life Sciences
Quantum Computing and its Impact on the Life Science Industry
Quantum computing uses quantum mechanics principles to solve certain complex mathematical problems faster than classical computers. Whilst classical computers use binary “bits” to perform calculations, quantum computers use quantum bits…
Life Sciences Perspectives
AI & Drug Discovery Symposium: Revolutionizing the Future of Medicine
Jumpstart your week with a deep dive into the future of medicine as part of Goodwin’s exclusive programming during the BIO International Convention in Boston. Join us for a dynamic…
Biosimilars Law Bulletin
Continued Investment in AI Drug Discovery Points to Potential Future Significance of Inventorship in Biosimilar Litigation
By Andrew Stewart, Brian Rosenbloom
On December 3, 2024, Bristol Myers Squibb announced a collaboration agreement with three-year-old startup AI Proteins.[1] According to its founder, Chris Bahl, PhD, AI Proteins uses “AI, synthetic biology, and…
Healthcare Law Blog
Day 1 Notes from the 42nd Annual J.P. Morgan Healthcare Conference
By Eric Klein
At the first day of the J.P. Morgan Healthcare Conference, “[T]he answer to the ultimate question of life, the universe and everything is 42.” Recognize that famous line? No, it’s…
Louis Lehot Medium Blog
Strengthening the Flow of the Biotech Sector’s M&A Pipeline
By Louis Lehot
Author(s): Louis Lehot, Eric ChowThe biotechnology sector has long been characterized by its constant innovation, rapid technological progress, and unyielding commitment to combating diseases. These attributes are more than passingly related…